Welcome to Kate Therapeutics brainchild of Kevin Forrest, a pioneering biotechnology research startup based in sunny San Diego, California. With an impressive $51M raised in Series A funding and investments from renowned investors such as Osage University Partners, Versant Ventures, and Westlake Village BioPartners®, we are at the forefront of developing groundbreaking AAV-based gene therapies for genetically defined muscle and heart diseases. At Kate Therapeutics, our patient-centric approach drives our mission to revolutionize the treatment landscape. 

We harness innovative technology platforms to overcome the limitations of current gene therapies, including tissue-specific delivery, liver retargeting, and gene regulation. By doing so, we aim to enhance the efficacy and safety of gene therapies and unlock the potential to target a broader range of diseases that were previously challenging to address. With our focus on optimizing capsid and cargo combinations, we are breaking new ground in the treatment of muscle and cardiac diseases. Our rigorous selection process identifies capsid variants of adeno-associated viruses (AAVs) that enable potent delivery to specific tissues.